Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.…
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Entrada Therapeutics (NASDAQ: TRDA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 152 employees.
The shares were at 4.350 USD on 20 November 2026, down 37.4% over 52 weeks. Its 52-week range is 4.109 USD to 16.45 USD: the price is 73.6% below the high and 5.9% above the low.
Its market capitalisation is 170.30M USD.
Entrada Therapeutics reports return on equity of -47.0% and revenue down 43.9% year over year.
It holds more cash than debt, a net cash position of 145.70M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.